ArticleDrug delivery and translational research2026
Microneedle patch-based transnasal delivery of naloxone.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluates dissolving microneedle (MN) patches for naloxone (NAL) delivery via the transnasal route, addressing limitations seen with transdermal application of same and the limitations of conventional NAL intranasal sprays, which often require frequent redosing, particularly for long-acting opioids like fentanyl. MN patches composed of polyvinylpyrrolidone (PVP) and PVP/Chitosan were tested on porcine nasal mucosa. PVP patches achieved significantly higher 1-h cumulative permeation (7295.12 ± 2585.17 µg/cm²) compared to transdermal application (103 ± 15.18 µg/cm², p < 0.05). Over 24 h, cumulative permeation reached 13,113.20 ± 597.39 µg/cm² transnasally versus 4112.89 ± 773.40 µg/cm² transdermally (p < 0.05). Chitosan-PVP MN patches improved bioadhesion and demonstrated high 1-h cumulative permeation (3800.19 ± 940.51 µg/cm²). PVP MN patches with drug-loaded tips (MN/TO, where TO implies "tip only") delivered 933.90 ± 161.60 µg/cm² in 1 h that was also a remarkable increase over transdermal permeation (p < 0.05) but had lower 24 h permeation. Similar observation was seen with the PVP/Chitosan variant with drug loaded in just MN tips indicating that sustained delivery requires drug in both the tips and base. To further refine patch designs, a mathematical modeling framework was employed to simulate drug dissolution, permeation dynamics, and plasma concentration kinetics. Simulations demonstrated that optimized patches could achieve plasma profiles comparable to intranasal and intramuscular administration, while minimizing drug dose and patch size. Increasing drug concentration from 50 to 60 mg/ml decreased permeation, likely due to drug crystallization. Overall, MN patches showed consistent, sustained NAL delivery, providing an alternative option for efficient opioid overdose treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.